Prostate Cancer
Advertisement
Researchers performed a post hoc analysis on patient data from the randomized, phase 3 LATITUDE trial.
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Dr. Iagaru discusses the safety findings and clinical implications of his research.
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
The data were sourced from a deidentified US-based metastatic prostate cancer clinicogenomic database.
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
cN1 patients with PCa who undergo initial treatment with RT have worse PCSM outcomes than those treated with RP.
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
Dr. Gupta traces the trajectory of her career and describes her commitment to advancing the field through innovative trials.
Dr. James Sylora shares his career, patient care, and vision for surgical and therapy advancements in community urology.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
OS was compared using Cox proportional hazards models with IPTW adjusted for baseline characteristics.
Drs. Ambinder and Elsamra explore robotic surgery, including its applicability, patient benefits, and evolving role.
A combination of androgen annihilation therapy with radiotherapy was tested for recurrent metastatic prostate cancer.
Cohort 4 of the trial is the final dose-escalation phase and will be followed by a dose-expansion phase.
Dr. Kirsh discusses his distinguished career and the evolution of urology practice in the United States.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.